BTAI (BioXcel Therapeutics) Total Inventories : $1.53 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Total Inventories?

BioXcel Therapeutics's total inventories for the quarter that ended in Sep. 2024 was $1.53 Mil. BioXcel Therapeutics's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $2.10 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BioXcel Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-35.18.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BioXcel Therapeutics's Days Inventory for the three months ended in Sep. 2024 was 163.98.

Inventory Turnover measures how fast the company turns over its inventory within a year. BioXcel Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.56.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioXcel Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 9.82.

BioXcel Therapeutics Total Inventories Historical Data

The historical data trend for BioXcel Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Total Inventories Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

1.99

BioXcel Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Inventories	Get a 7-Day Free Trial															2.02	1.99	2.44	2.68	1.53

BioXcel Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

BioXcel Therapeutics (NAS:BTAI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

BioXcel Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

	Net-Net Working Capital Per Share (Q: Sep. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(40.387	+	0.75 * 0.003	+	0.5 * 1.525	-	134.525
-	0	-	0)	/	2.654
=	-35.18

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioXcel Therapeutics's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2024 )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
	=	2.1025	/	1.17	*	365 / 4
	=	163.98

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

BioXcel Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2024 )	/	Average Total Inventories (Q: Sep. 2024 )
	=	1.17	/	2.1025
	=	0.56

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioXcel Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	2.1025	/	0.214
	=	9.82

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

BioXcel Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

BX20:Germany

Address

555 Long Wharf Drive, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Executives

Richard I Steinhart	officer: Chief Financial Officer	125 ELM STREET, NEW CANAAN CT 06840
Javier Rodriguez	officer: SEE REMARKS	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Frank Yocca	officer: Chief Scientific Officer	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vimal Mehta	director, officer: CEO, President, Secretary	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vincent O'neill	officer: Chief Medical Officer	2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Matthew T. Wiley	officer: CHIEF COMMERCIAL OFFICER	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Krishnan Nandabalan	director, 10 percent owner	228 VILLAGE POND ROAD, GUILFORD CT 06437
Alka Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello	10 percent owner	10 TEMPLETON ROAD, WALLINGFORD CT 06492
Pardeep Kumar Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437